LUND, Sweden, Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare ...

BARDA tapped a team of Fred Hutch Cancer Center biostatisticians to determine the biomarkers that will serve as predictors of ...

Infants who received early MMR vaccination before 8.5 months of age exhibited waning protection later in life and blunted antibody responses to subsequent vaccination.

Plasmacytoid dendritic cells (pDC) primarily function as weak antigen-presenting cells (APC), but have also been shown to ...

Objective To evaluate the association between thyroid disease and diabetes markers. Design Retrospective cohort study. Setting The study was conducted in a diagnostic setting where the primary care ...

Adalimumab trough levels of 4.0 mg/L or higher among patients with RA were linked to greater treatment response and achievement of remission.

At Dyadic, we remain committed to leveraging our innovative C1 and Dapibus protein production platforms to address some of the most pressing ...

10, 2024 — A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond to prior ...

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, announces the launch of its high-performance HPV IgG ELISA Kit for the sensitive and specific ...

Tularemia cases in the U.S. rose by 56% from 2011 to 2022, with central states and American Indian communities most affected, highlighting diagnostic advancements and health disparities.

BLM-07D1 is under clinical development by Systimmune and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate ...

High serum CXCL13 levels are predictive of treatment failure with first-line MTX among patients with early RA.